Identification of genetic determinants of bedaquiline resistance in Mycobacterium tuberculosis in Ural region, Russia
Open Access
- 5 March 2024
- journal article
- research article
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (3) , e0374923
Abstract
Collecting data on rare Mycobacterium tuberculosis ( Mtb ) clinical isolates with resistance to the new anti-tuberculosis drug bedaquiline is an important task for improving antimicrobial susceptibility testing methods. Nanopore whole genome sequencing, the proportion method on Middlebrook 7H11 medium, and BACTEC MGIT 960 assays were used to analyze genotypic and phenotypic resistance to bedaquiline. We found four mutations: atpE I66M, atpE А63Р, Rv0678 А36Т, and Rv0678 S53P in five isolates with different levels of phenotypic bedaquiline resistance. IMPORTANCE: Bedaquiline (BDQ) is a new anti-tuberculosis drug. The phenotypic and genotypic data describing the mechanism of drug resistance are critical for the design of rapid and accurate diagnostic tests. We consider that our work, which describes genotypic and phenotypic resistance to BDQ, can contribute to the standardization of drug susceptibility testing.Keywords
This publication has 17 references indexed in Scilit:
- Site-directed mutagenesis of Mycobacterium tuberculosis and functional validation to investigate potential bedaquiline resistance-causing mutationsScientific Reports, 2023
- Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysisThe Lancet Microbe, 2023
- Minimap2: pairwise alignment for nucleotide sequencesBioinformatics, 2018
- Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort StudyEBioMedicine, 2018
- Bedaquiline Resistance: Its Emergence, Mechanism, and PreventionClinical Infectious Diseases, 2017
- Removing the bottleneck in whole genome sequencing of Mycobacterium tuberculosis for rapid drug resistance analysis: a call to actionInternational Journal of Infectious Diseases, 2017
- Unexpected high prevalence of resistance-associatedRv0678variants in MDR-TB patients without documented prior use of clofazimine or bedaquilineJournal of Antimicrobial Chemotherapy, 2016
- Qualimap 2: advanced multi-sample quality control for high-throughput sequencing dataBioinformatics, 2015
- Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2014
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005